Medicines Development in Alzheimer's disease
The Graybook supplementary e-text on Medicines Development in Alzheimer´s disease is designed to provide a clear explanation of the basic facts how new medicines are tested in this field.
The sections are as follows:
- Foreword
- Introduction
- Brain Basics
- Pathophysiology
- Symptoms
- Diagnostic criteria and tests
- Current treatments
- Symptomatic vs disease modifying approaches
- Regulatory Guidelines
- Clinical Trial Design and Phases
- Endpoints: clinical
- Endpoints: biochemical
- Endpoints:neuroimaging, other
- Key trial methodology issues
- Prevention studies
- Combination studies
- Appendix
The e-text is intended to be useful to anyone needing a concise summary about how new treatments for Alzheimer's disease are developed. While not a text on Alzheimer’s diseaseit6self, background information on the condition is included to the extent needed for understanding the corresponding development aspects. A short chapter on the basics of brain function has also been included for those new to this area.
The supplement is available at an additional cost to licensees of the Gray Book Standard or Professional version.